



## Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer


### Supplementary Materials



**Supplementary Figure S1: Effect of 5-aza-dC treatment on IGF1R expression.** Cells were treated with the indicated time or dose of 5-aza-dC. IGF1R expression was determined by Western blotting.



**Supplementary Figure S2: Cytotoxicity of AG-1024 or BI 836845.** Cells were treated with the indicated dose of AG-1024 or BI 836845 for 72 h. Cellular viability was determined by MTT assay.



**Supplementary Figure S3: Effect of combination WZ4002 and U0126 in cells with acquired resistance to WZ4002.** WZ4002-resistant cells were treated with WZ4002, U0126, or a combination of two drugs for 72 h. Cellular viability was determined by MTT assay.